Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Hideto Kameda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Product Surveillance, Postmarketing, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Using data from a postmarketing surveillance, this interim subgroup analysis investigated the safety of sarilumab in younger (<65 years) and older patients (≥65 and ≥75 years) with rheumatoid arthritis.
Methods
During this interim analysis, patients who were treated with sarilumab in Japan were enrolled between June 2018 and 2021. Data collected by 12 January 2022 were analysed, with adverse drug events monitored over 52 weeks.
Results
Of 972 patients with available data, the proportion of patients aged <65 years, ≥65 years, and ≥75 years was 40.8%, 59.2%, and 27.8%, respectively. Most patients (95.5%) received the standard 200 mg dose of sarilumab as the initial dose. Adverse drug reactions were reported in 24.6% of patients, with serious events accounting for 6.4% of cases. No malignancy and low incidences of adverse drug reactions of special interest were reported across all age groups (<65 years, 7.8%; ≥65 years, 8.2%; ≥75 years, 8.5%). When stratified by absolute neutrophil count above and below the lower limit of normal, there were no numerical differences in incidences of serious and non-serious infections between age groups.
Conclusions
Regardless of age, sarilumab therapy was well tolerated by patients with rheumatoid arthritis, with no new safety signals reported in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
- Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
- Medical Affairs, Sanofi K.K., Tokyo, Japan.
- Global Medical Affairs, Sanofi US, Bridgewater, NJ, USA.
- Patient Safety & Pharmacovigilance, Sanofi-Aventis (Schweiz) ag 3, Vernier, Switzerland.
ORCID-Profile: Hideto Kameda
Zitieren
APA
Kameda, H., Tasaka, S., Takahashi, T., Suzuki, K., Soeda, N., van Hoogstraten, H., Diab, R., & Tanaka, Y. (2024). Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study. Modern Rheumatology. https://doi.org/10.1093/mr/roae051
Vancouver
Kameda H, Tasaka S, Takahashi T, Suzuki K, Soeda N, van Hoogstraten H, et al. Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study. Modern Rheumatology. 2024. doi:10.1093/mr/roae051
BibTeX
@article{Kameda2024,
author = {Kameda, Hideto and Tasaka, Sadatomo and Takahashi, Toshiya and Suzuki, Katsuhisa and Soeda, Naoki and van Hoogstraten, Hubert and Diab, Remco and Tanaka, Yoshiya},
title = {Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae051}
}
EUVIMED